Traders should monitor upcoming clinical updates in mid-2026 (monotherapy) and second half of 2026 (combination) for confirmation of clinical activity; positive data could drive significant upside in this low-market-cap biotech. Synergy with pembrolizumab may enhance partnership or licensing potential.
PYXS drugs
PYXS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 20 $1.70entry
- T+1 · 7mo ago +0.59%α +1.24% · $1.71
- T+5 · 7mo ago +3.53%α +2.62% · $1.76
- T+20 · 6mo ago +18.82%α +14.62% · $2.02
- T+60 · 4mo ago +42.94%α +36.16% · $2.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pyxis Oncology announced preclinical data showing that a mouse analog of its drug MICVO (maMICVO) demonstrated dose-dependent tumor growth inhibition and synergistic anti-tumor activity when combined with anti-PD-1 therapy in an immunotherapy-refractory head and neck cancer model. These findings support ongoing clinical trials of MICVO as monotherapy and in combination with pembrolizumab for recurrent/metastatic HNSCC.
Key Facts
- Preclinical data show maMICVO monotherapy inhibited tumor outgrowth in a syngeneic HNSCC model in a dose-dependent manner, with 6 mg/kg showing strongest effect
- Combination of maMICVO and anti-mouse PD-1 showed synergistic anti-tumor activity in an immunotherapy-refractory model, with greater tumor control than either agent alone
- maMICVO modulated the tumor immune environment by reducing regulatory T cells (Tregs), increasing CD8+ T cell-to-Treg ratio, and enhancing progenitor exhausted T cells responsive to anti-PD-1
- Data to be presented at AACR 2026; supports ongoing Phase 1/2 trials of MICVO alone and with pembrolizumab in R/M HNSCC
- MICVO has Fast Track Designation from FDA for R/M HNSCC previously treated with platinum and anti-PD-(L)1 therapy
Financial Impact
Non-material at this stage; preclinical data support clinical development but no revenue or earnings impact expected in near term
Risk Factors
- Preclinical results may not translate to clinical efficacy in humans
- Clinical trial delays or safety issues could derail development
- Low market cap ($107M) implies high risk; dependent on successful trial outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276488 |
Track record
25 reports on PYXS
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +21.03% at T+20 after the Sep 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.41 −12.42% settles Dec 4
- Nov 3, 202613d ago SC 13G/A Bearish 5/10 Entry $1.64 Now $1.41 +14.02% settles Dec 2
- Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
- Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
- Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
- Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
- Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers